RU2022101891A - Способы применения cd32b x cd79b-связывающих молекул при лечении воспалительных заболеваний и расстройств - Google Patents

Способы применения cd32b x cd79b-связывающих молекул при лечении воспалительных заболеваний и расстройств Download PDF

Info

Publication number
RU2022101891A
RU2022101891A RU2022101891A RU2022101891A RU2022101891A RU 2022101891 A RU2022101891 A RU 2022101891A RU 2022101891 A RU2022101891 A RU 2022101891A RU 2022101891 A RU2022101891 A RU 2022101891A RU 2022101891 A RU2022101891 A RU 2022101891A
Authority
RU
Russia
Prior art keywords
cd32b
cd79b
seq
binding molecule
amino acid
Prior art date
Application number
RU2022101891A
Other languages
English (en)
Russian (ru)
Other versions
RU2022101891A3 (cg-RX-API-DMAC10.html
Inventor
Вэй Чэнь
Пол А. МУР
Наимиш Бхарат ПАНДЬЯ
Эзио Бонвини
Джон Марк ВИГГИНТОН
Original Assignee
Мэкроудженикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мэкроудженикс, Инк. filed Critical Мэкроудженикс, Инк.
Publication of RU2022101891A publication Critical patent/RU2022101891A/ru
Publication of RU2022101891A3 publication Critical patent/RU2022101891A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2022101891A 2016-06-07 2017-06-06 Способы применения cd32b x cd79b-связывающих молекул при лечении воспалительных заболеваний и расстройств RU2022101891A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662346717P 2016-06-07 2016-06-07
US62/346,717 2016-06-07
US201662432328P 2016-12-09 2016-12-09
US62/432,328 2016-12-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2018145971A Division RU2772434C2 (ru) 2016-06-07 2017-06-06 Способы применения cd32b x cd79b-связывающих молекул при лечении воспалительных заболеваний и расстройств

Publications (2)

Publication Number Publication Date
RU2022101891A true RU2022101891A (ru) 2022-02-07
RU2022101891A3 RU2022101891A3 (cg-RX-API-DMAC10.html) 2025-06-24

Family

ID=60578080

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2022101891A RU2022101891A (ru) 2016-06-07 2017-06-06 Способы применения cd32b x cd79b-связывающих молекул при лечении воспалительных заболеваний и расстройств

Country Status (11)

Country Link
US (1) US20190322741A1 (cg-RX-API-DMAC10.html)
EP (1) EP3464378A4 (cg-RX-API-DMAC10.html)
JP (3) JP2019521103A (cg-RX-API-DMAC10.html)
KR (3) KR20250021614A (cg-RX-API-DMAC10.html)
CN (1) CN109311990A (cg-RX-API-DMAC10.html)
AU (1) AU2017278329B2 (cg-RX-API-DMAC10.html)
BR (1) BR112018075303A2 (cg-RX-API-DMAC10.html)
MX (2) MX2018015265A (cg-RX-API-DMAC10.html)
RU (1) RU2022101891A (cg-RX-API-DMAC10.html)
TW (1) TW201742633A (cg-RX-API-DMAC10.html)
WO (1) WO2017214096A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201790719A1 (ru) * 2014-09-26 2017-07-31 Макродженикс, Инк. Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
EP3532497B1 (en) * 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
JP2022513338A (ja) * 2018-10-03 2022-02-07 ネペンザ・バイオサイエンシズ・エルエルシー 抗ｃｄ７９抗体およびその使用
CN114502587A (zh) * 2019-07-30 2022-05-13 普瑞文森生物有限公司 通过非耗竭性b细胞抑制剂降低免疫原性的方法和组合物
KR20220091458A (ko) * 2019-07-30 2022-06-30 프로벤션 바이오, 인코포레이티드 비-고갈성 b 세포 억제제에 의한 면역원성을 감소시키기 위한 방법 및 조성물
WO2021207681A1 (en) * 2020-04-10 2021-10-14 The Board Of Trustees Of The Leland Stanford Junior University Targeted reduction of activated immune cells
KR20230113312A (ko) * 2020-11-01 2023-07-28 프로벤션 바이오, 인코포레이티드 루푸스 치료 방법 및 조성물
CA3231174A1 (en) * 2021-08-02 2023-02-09 Innovent Biologics (Suzhou) Co., Ltd. Anti-cd79bxcd3 bispecific antibody and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963510B2 (en) * 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US11384149B2 (en) * 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk) * 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
AU2016207758C1 (en) * 2015-01-13 2020-05-28 New Zealand Institute For Bioeconomy Science Limited Agricultural composition

Also Published As

Publication number Publication date
US20190322741A1 (en) 2019-10-24
JP2019521103A (ja) 2019-07-25
BR112018075303A2 (pt) 2019-04-30
RU2018145971A3 (cg-RX-API-DMAC10.html) 2020-09-03
AU2017278329B2 (en) 2024-08-08
MX2018015265A (es) 2019-09-06
KR20220143769A (ko) 2022-10-25
KR20190016079A (ko) 2019-02-15
WO2017214096A1 (en) 2017-12-14
RU2018145971A (ru) 2020-07-10
KR20250021614A (ko) 2025-02-13
CN109311990A (zh) 2019-02-05
JP2022120061A (ja) 2022-08-17
TW201742633A (zh) 2017-12-16
EP3464378A1 (en) 2019-04-10
JP2024102146A (ja) 2024-07-30
EP3464378A4 (en) 2020-06-17
MX2024005841A (es) 2024-05-27
AU2017278329A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
JP2019521103A5 (cg-RX-API-DMAC10.html)
JP2022518770A5 (cg-RX-API-DMAC10.html)
JP2017522043A5 (cg-RX-API-DMAC10.html)
JP2018509413A5 (cg-RX-API-DMAC10.html)
JP2019162105A5 (cg-RX-API-DMAC10.html)
AU2017319318B2 (en) Anti-CD3 antibody formulations
JP2017079785A5 (cg-RX-API-DMAC10.html)
JP2021061854A5 (cg-RX-API-DMAC10.html)
TWI890481B (zh) 雙特異性抗體
JP2021522801A5 (cg-RX-API-DMAC10.html)
FI3250610T3 (fi) Fcrn-vasta-aineita ja menetelmiä niiden käyttämiseksi
US20120189621A1 (en) Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists
JP2011520898A5 (cg-RX-API-DMAC10.html)
JP2014511844A5 (cg-RX-API-DMAC10.html)
JP2018501813A5 (cg-RX-API-DMAC10.html)
RU2008152443A (ru) Антитела высокой аффинности к il-6-рецептору человека
JP2023113636A5 (cg-RX-API-DMAC10.html)
ES2769123T3 (es) Anticuerpos de quimiocinas PAN ELR+ CXC
JP2016507555A5 (cg-RX-API-DMAC10.html)
JP2021510737A5 (cg-RX-API-DMAC10.html)
JP2018501254A5 (cg-RX-API-DMAC10.html)
JP2018515532A5 (cg-RX-API-DMAC10.html)
RU2018107693A (ru) Комбинированные виды лечения и их варианты применения и способы
JP2022512713A5 (cg-RX-API-DMAC10.html)
JP2022521956A5 (cg-RX-API-DMAC10.html)